ReviewClinical & developmental immunology2013
Site-specific immunosuppression in vascularized composite allotransplantation: prospects and potential.
Review in Clinical & developmental immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- The Transformative Journey of Vascularized Composite Allotransplantation: Advances, Challenges, and Future Directions.Transplantation direct · 2026Article
- Differentiation of acute versus chronic skin rejection in a rodent model of vascularized composite allotransplantation.Frontiers in immunology · 2025Article
- Retinal transplant immunology and advancements.Stem cell reports · 2024Review
- Nerve Wrap for Local Delivery of FK506/Tacrolimus Accelerates Nerve Regeneration.International journal of molecular sciences · 2024Article
- A Reversibly Thermoresponsive, Theranostic Nanoemulgel for Tacrolimus Delivery to Activated Macrophages: Formulation and In Vitro Validation.Pharmaceutics · 2023Article
- Tacrolimus-Eluting Disk within the Allograft Enables Vascularized Composite Allograft Survival with Site-Specific Immunosuppression without Systemic Toxicity.Pharmaceutical research · 2022Article
- The Positive Impact of Donor Bone Marrow Cells Transplantation into Immunoprivileged Compartments on the Survival of Vascularized Skin Allografts.Archivum immunologiae et therapiae experimentalis · 2021Article
- The Effects of Tacrolimus on Tissue-Specific, Protein-Level Inflammatory Networks in Vascularized Composite Allotransplantation.Frontiers in immunology · 2021Article
- Large Animal Models of Vascularized Composite Allotransplantation: A Review of Immune Strategies to Improve Allograft Outcomes.Frontiers in immunology · 2021Review
- Pharmacokinetics and Biodistribution of Tacrolimus after Topical Administration: Implications for Vascularized Composite Allotransplantation.Pharmaceutical research · 2020Article
- Treg-inducing microparticles promote donor-specific tolerance in experimental vascularized composite allotransplantation.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Delivery of Rapamycin Using In Situ Forming Implants Promotes Immunoregulation and Vascularized Composite Allograft Survival.Scientific reports · 2019Article
- Article
- Mycophenolic Acid for Topical Immunosuppression in Vascularized Composite Allotransplantation: Optimizing Formulation and Preliminary Evaluation of Bioavailability and Pharmacokinetics.Frontiers in surgery · 2018Article
- Tracheal reconstruction with a free vascularized myofascial flap: preclinical investigation in a porcine model to human clinical application.Scientific reports · 2017Article
- Clinical Considerations for Vascularized Composite Allotransplantation of the Eye.The Journal of craniofacial surgery · 2016Review
- Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration.Transplant international : official journal of the European Society for Organ Transplantation · 2016Review
- An engineered multicomponent bone marrow niche for the recapitulation of hematopoiesis at ectopic transplantation sites.Journal of hematology & oncology · 2016Article
- Emerging Implications for Extracellular Matrix-Based Technologies in Vascularized Composite Allotransplantation.Stem cells international · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin is the most immunogenic component of a vascularized composite allograft (VCA) and is the primary trigger and target of rejection. The skin is directly accessible for visual monitoring of acute rejection (AR) and for directed biopsy, timely therapeutic intervention, and management of AR. Logically, antirejection drugs, biologics, or other agents delivered locally to the VCA may reduce the need for systemic immunosuppression with its adverse effects. Topical FK 506 (tacrolimus) and steroids have been used in clinical VCA as an adjunct to systemic therapy with unclear beneficial effects. However, there are no commercially available topical formulations for other widely used systemic immunosuppressive drugs such as mycophenolic acid, sirolimus, and everolimus. Investigating the site-specific therapeutic effects and efficacy of systemically active agents may enable optimizing the dosing, frequency, and duration of overall immunosuppression in VCA with minimization or elimination of long-term drug-related toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.